# Thymosin Alpha-1: A Medicine Almost Everywhere But Here > Thymosin Alpha-1: Research Overview — Peptide Asia — A cited research overview of thymosin alpha-1 (thymalfasin), an immunomodulatory peptide approved as a medicine in more than 35 countries but not by the FDA. Mechanism, sepsis and COVID-19 trial results, and safety cautions. **02 / RESEARCH PEPTIDE FUNDAMENTALS — LEAD COMPOUND** An immune-modulating peptide registered as a drug in dozens of countries for four decades, and the clearest illustration on this desk of how unevenly regulatory geography can travel. ## The short version Thymosin alpha-1 (brand name Zadaxin, generic thymalfasin) is a 28-amino-acid peptide that nudges the immune system toward a stronger, more coordinated response. It is approved as a medicine in more than 35 countries [7] — a genuinely large international footprint — but it has never received FDA marketing approval in the United States, where it remains available only through investigational or compounding channels. Decades of use abroad, mostly for chronic hepatitis and as a cancer-therapy adjunct, built a reputation for being well tolerated, with mild injection-site reactions as the most common complaint [7]. But the largest, most rigorous trial ever run on it — a 2025 study of 1,106 adults with sepsis — found no significant survival benefit [6], a result worth sitting with rather than skipping past. This page reports what the studies found, in the country or setting where each one was run, and it never turns a study finding into a recommendation for what a person should do. ## What it is Thymosin alpha-1 is a 28-amino-acid polypeptide, acidic in charge, with no aromatic amino acids and no internal disulfide bonds holding it together. It is cleaved in the body from a larger 113-amino-acid precursor called prothymosin alpha. Its N-terminal end carries an acetyl group, a small chemical modification that turns out to be essential for its biological activity — remove it, and the peptide loses potency. The synthetic drug version, thymalfasin, is manufactured to be sequence-identical to the naturally occurring peptide, first isolated and sequenced from calf thymus tissue in 1977 [12]. ## How it works Thymosin alpha-1 sits at the interface between the immune system's fast, generic first response and its slower, targeted one. It engages Toll-like receptors — notably TLR2 and TLR9 — on dendritic cells and monocytes, prompting those cells to mature, produce signalling molecules, and present antigens more effectively to T cells. That, in turn, drives T-cell maturation and steers the immune response toward a Th1-dominant, infection-fighting posture. What makes the mechanism unusual is its second, opposing arm: thymosin alpha-1 can also activate an enzyme pathway (indoleamine 2,3-dioxygenase, or IDO) in dendritic cells that generates regulatory T cells — the immune system's brakes [11]. In other words, the same peptide that revs up an immune response also builds in a check against that response running away into damaging inflammation. That dual signature is why it has been studied in settings as different as sepsis, where inflammation needs braking, and immune-reconstitution, where the immune system needs a push. ## What the research shows *Sepsis — the null result that matters most.* The phase-3 TESTS trial, the largest and most rigorous study run on thymosin alpha-1 to date, randomized 1,106 adults with sepsis across 22 centres. Twenty-eight-day mortality was 23.4% with thymosin alpha-1 versus 24.1% with placebo — no meaningful difference (hazard ratio 0.99, P=0.93) [6]. This overturned the cautious optimism built on an earlier, smaller trial. *Sepsis — the earlier, marginal signal.* The multicentre ETASS trial of 361 patients with severe sepsis found 28-day mortality of 26.0% with thymosin alpha-1 versus 35.0% with control care — a nine-percentage-point gap that fell just short of conventional statistical significance [10]. It was this result, not the later null trial, that shaped much of the compound's earlier reputation. *COVID-19.* A retrospective review of 76 patients with severe COVID-19 found significantly lower mortality with thymosin alpha-1 (11.1% versus 30.0%), and the peptide appeared to restore exhausted T cells in patients with severe lymphocyte depletion [8]. Retrospective, uncontrolled data of this kind carries real limitations, but the T-cell finding is mechanistically consistent with how the peptide is understood to work. *Cancer.* A reappraisal of the oncology literature positions thymosin alpha-1 as a combination-therapy adjunct alongside chemotherapy and immunotherapy in melanoma, liver cancer and lung cancer, working through dendritic-cell activation and potentially easing some of the toxicity associated with checkpoint-inhibitor drugs [9]. *Long international use.* A comprehensive literature review spanning four decades of clinical use reports standard single doses of 0.8-6.4 mg and describes the peptide as generally well tolerated, dominated by mild, local injection-site reactions [7]. ## Reported effects, cautions & safety Community and forum reports about thymosin alpha-1 skew mild — anecdotal, not clinical evidence, and never tied to a specific dose. *Reported benefits:* the most common description is fewer or milder seasonal colds, and a faster bounce-back after a stretch of feeling run-down. Some describe steadier energy while recovering from a chronic illness. A recurring theme, consistent with its documented profile, is that many people report no noticeable effect at all beyond feeling generally well. *Reported adverse effects:* mild injection-site redness, itching or stinging is by far the most mentioned complaint, occasionally paired with a brief flu-like or achy day. A distinct, non-medical complaint shows up often too: cost and access, since it is not a routinely available US product, alongside worry about the purity and identity of unregulated research-grade material. *Cited cautions from the clinical literature:* - **A theoretical caution in autoimmune disease**, since the peptide can promote a more active immune response, though it also carries a counterbalancing regulatory arm and circulating levels are actually reduced in some autoimmune conditions. - **A theoretical caution for solid-organ transplant recipients**, whose treatment depends on deliberate immunosuppression that an immune-activating peptide could in principle work against. - **Injection-site reactions** remain the dominant documented adverse event across large-scale post-marketing surveillance, with no organ toxicity identified at studied doses. - **Efficacy expectations should be tempered**: the largest, most rigorous trial to date found no mortality benefit in sepsis [6], a result that should curb assumptions built on smaller, earlier studies. - **No US marketing approval**, and material obtained as unregulated research-grade peptide sits outside the quality-assurance standards that apply to an approved medicine. ## Where it fits in the global research map Thymosin alpha-1 is the sharpest case study this desk has for how peptide research and peptide regulation diverge. Approved as thymalfasin in more than 35 countries [7], it has accumulated decades of real-world clinical use and a genuinely large trial base — including the 22-centre TESTS study [6] — that its US-only regulatory status alone would not predict. Compare that to [BPC-157](/bpc-157) and [MOTS-c](/mots-c), which are approved nowhere and consequently have far thinner human evidence, or to [semaglutide](/semaglutide), which took the opposite route: FDA approval first, then a dense trial programme built around it. See the [comparison page](/compare) for how the four line up. ![Thymosin Alpha-1 research illustration](/images/thymosin-alpha-1.webp) --- Peptide Asia draws its own map from published citations, not from borders or brochures — read it as a literature digest, never as a clinic, a shop, or a prescription.